Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
This large, randomized, placebo-controlled trial showed the efficacy of omalizumab, an injectable anti–IgE humanized monoclonal antibody, in the treatment of chronic idiopathic urticaria.
Chronic idiopathic urticaria (also called chronic spontaneous urticaria) is defined as itchy hives that last for at least 6 weeks, with or without angioedema,...
Alternative Titles
Full title
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1315629395
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1315629395
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1215372
